The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available
WP5-SA4 – Updated report including the complete dataset on indirect comparisons published on EUnetHTA homepage. Find the Joint Assessment here.
EMA and EUnetHTA meet in London on May 8, 2015
Following the agreed schedule of biannual meetings between EUnetHTA and the EMA, the next meeting is held tomorrow (May 8, 2015) in London The final draft agenda for the meeting is available here. The minutes of the meeting will be made publicly available on the EMA-EUnetHTA cooperation page.
Publication of a JA2 methodological guideline – Methods for health economic evaluations
The 2nd JA2 methodological guideline has now been published You can find the methodological guideline and the comments and provided answers in the output section.
[CLOSED] Public consultation on the Position paper on how to best formulate research recommendations for primary research arising from HTA reports.
Deadline extended – Public consultation on the Position paper on how to best formulate research recommendations for primary research arising from HTA reports. In order to gather as much feedback as possible, WP7 Subgroup 2 has decided to extend the public consultation period on the position paper on how to best formulate research recommendations until June […]
Version 2.1 of the HTA Core Model® available
WP8 has published the final version 2.1 of the HTA Core Model®. It is available for HTA projects within the HTA Core Model® Online at www.corehta.info. All contents are also available as a pdf document, find it here. Version 2.1 contains a completely updated legal domain and several changes to the HTA ontology. Key changes […]
[CLOSED] Public consultation of the draft methodological guideline “Internal validity of non-randomised studies (NRS) on interventions”
We are pleased to announce that as of today, 20 April, 2015, the draft methodological guideline “Internal validity of non-randomised studies (NRS) on interventions”, produced within WP7 – Subgroup 3, has entered the public consultation phase. This consultation will take place between 20 April and 15 May 2015. Objective of the methodological guideline EUnetHTA´s methodological […]
[CLOSED] Public consultation on the position paper on how to decide on the appropriate study design for primary research arising from HTA
WP7 Subgroup 2 is pleased to announce the public consultation on the Position paper on how to decide on the appropriate study design. This consultation will take place between April 14 and May 29, 2015 (noon). Objective of the position paper This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic […]
WP5 Strand A – Procedure Manual V4 is available
The fourth version of the Procedure Manual has been compiled, incorporating comments received from Strand A members and the Stakeholder Advisory Group of WP5. This document describes processes planned for conducting pilot rapid assessments for pharmaceuticals. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. […]
[CLOSED] Public consultation of the Draft Project Plan on “Transcatheter mitral valve repair in adults with chronic mitral valve regurgitation”
We are pleased to announce that as of today the Draft Project Plan on “Transcatheter mitral valve repair in adults with chronic mitral valve regurgitation”, produced within WP5 Strand B, has entered the public consultation phase. This consultation will take place between 30/03 and 22/04 2015. Objective of Draft Project Plan The aim of the […]
Scientific needs of HTA – methodological issues requiring further research attention
Further development of HTA methodologies is a must if HTA shall stay relevant and continue to be the contemporary approach to inform decision-making in healthcare. EUnetHTA was established to create an effective and sustainable network for HTA across Europe – we work together to develop reliable, timely, transparent and transferable information to contribute to HTAs in European […]
